Identity and synonyms
GDF-8 is myostatin; it must not be described as a myostatin inhibitor based only on a supplier listing.
Protein or biologic · Protein or protein analogue
Detailed molecular class: Protein/biologic; confirm exact product
Supplied sequence or chemical reference
Mechanism
GDF-8 is myostatin, a TGF-β-family signal limiting muscle mass; it is not a myostatin inhibitor.
Evidence and critical reading
Reported scientific and empirical uses
Reported muscle and performance
Included because it appears in muscle-product catalogs, with a major risk of interpreting the name backward.
Human evidence
Myostatin loss-of-function models and inhibitor trials do not establish anabolic efficacy of administered GDF-8.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
Myostatin loss-of-function models and inhibitor trials do not establish anabolic efficacy of administered GDF-8.
Myostatin loss-of-function models and inhibitor trials do not establish anabolic efficacy of administered GDF-8.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
This record does not verify FDA/EMA authorization of the commercial identity. Where a specific medicine/product exists, jurisdiction/indication are detailed in cited sources; they do not transfer to supplier material.
Adverse effects and unknowns
Resolve whether material is active ligand, propeptide or another product. Do not assign follistatin or ACE-031 doses/outcomes.
Contraindications
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
GDF-8 · 35 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT07047144 · A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular AtrophyRegistry status: RecruitingLast update posted: October 2, 2026Query verification: October 16, 2026
NCT07804719 · Possible Sarcopenia, Sarcopenia, and Functional Status in Patients With Primary Sjögren's SyndromeRegistry status: Active, not recruitingLast update posted: September 24, 2026Query verification: October 16, 2026
NCT07435129 · Phase 2 Study Evaluating Apitegromab for the Treatment of FSHDRegistry status: RecruitingLast update posted: September 2, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID9139826
Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member.
McPherron AC, Lawler AM, Lee SJ.
October 16, 2026
- SEARCH-PUBMED-gdf-8
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026